海王英特龙2023 中期报告

香港聯合交易所有限公司（「聯交所」）GEM的特色 CHARACTERISTICS OF GEM OF THE STOCKEXCHANGE OF HONG KONG LIMITED (THE “STOCKEXCHANGE”) GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方可作出投資決定。 GEM has been positioned as a market designed to accommodatesmall and mid-sized companies to which a higher investment riskmay be attached than other companies listed on the Stock Exchange.Prospective investors should be aware of the potential risks ofinvesting in such companies and should make the decision to investonly after due and careful consideration. 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於聯交所主板買賣之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 Given that the companies listed on GEM are generally small andmidsized companies, there is a risk that securities traded on GEM maybe more susceptible to high market volatility than securities tradedon the Main Board of the Stock Exchange and no assurance is giventhat there will be a liquid market in the securities traded on GEM. 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Hong Kong Exchanges and Clearing Limited and the Stock Exchange take noresponsibility for the contents of this report, make no representation as to itsaccuracy or completeness and expressly disclaim any liability whatsoever forany loss howsoever arising from, or in reliance upon the whole or any part ofthe contents of this report. 本報告的資料乃遵照聯交所的《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供有關深圳市海王英特龍生物技術股份有限公司（「本公司」）的資料。本公司的董事（「董事」）願就本報告的資料共同及個別地承擔全部責任。各董事在作出一切合理查詢後，確認就其所知及所信，本報告所載資料在各重要方面均屬準確完備，沒有誤導或欺詐成份，且並無遺漏其他事項，足以令致本報告或其所載任何陳述產生誤導。 This report, for which the directors (the “Directors”) of Shenzhen NeptunusInterlong Bio-technique Company Limited (the “Company”) collectively andindividually accept full responsibility, includes particulars given in compliancewith the Rules Governing the Listing of Securities on GEM of the StockExchange (the “GEM Listing Rules”) for the purpose of giving informationwith regard to the Company. The Directors of the Company, having madeall reasonable enquiries, confirm that to the best of their knowledge andbelief the information contained in this report is accurate and complete inall material respects and not misleading or deceptive, and there are no othermatters the omission of which would make any statement herein or thisreport misleading. Interim Results (Unaudited)中期業績（未經審核） 本公司董事會（「董事會」）欣然呈列本公司及其附屬公司（統稱「本集團」）截至二零二三年六月三十日止六個月（「報告期間」）之未經審核簡明綜合中期財務報表，連同二零二二年同期之未經審核比較數字。 The board of directors (the “Board”) of the Company is pleased to presentthe unaudited condensed consolidated interim financial statements of theCompany and its subsidiaries (collectively the “Group”) for the six monthsended 30 June 2023 (the “Reporting Period”), together with the unauditedcomparative figures for the corresponding period of 2022. Condensed Consolidated Statement of Profitor Loss and Other Comprehensive Income(Unaudited) 簡明綜合損益及其他全面收益表（未經審核） For the three months and six months ended 30 June 2023截至二零二三年六月三十日止三個月及六個月 Condensed Consolidated Statement of Profit or Loss andOther Comprehensive Income (Unaudited)簡明綜合損益及其他全面收益表（未經審核） For the three months and six months ended 30 June 2023截至二零二三年六月三十日止三個月及六個月 Condensed Consolidated Statement ofFinancial Position (Unaudited)簡明綜合財務狀況表（未經審核） As at 30 June 2023於二零二三年六月三十日 InventoriesTrade and other receivablesShort-term bank depositsBank balances and cash Condensed Consolidated Statement of Financial Position (Unaudited)簡明綜合財務狀況表（未經審核） As at 30 June 2023於二零二三年六月三十日 Condensed Consolidated Statement of Financial Position (Unaudited)簡明綜合財務狀況表（未經審核） As at 30 June 2023於二零二三年六月三十日 Condensed Consolidated Statement ofChanges in Equity (Unaudited)簡明綜合權益變動表（未經審核） For the six months ended 30 June 2023截至二零二三年六月三十日止六個月 Condensed Consolidated Statementof Cash Flows (Unaudited)簡明綜合現金流量表（未經審核） For the six months ended 30 June 2023截至二零二三年六月三十日止六個月 Condensed Consolidated Statement of Cash Flows (Unaudited)簡明綜合現金流量表（未經審核） For the six months ended 30 June 2023截至二零二三年六月三十日止六個月 Notes to the Condensed Consolidated InterimFinancial Statements簡明綜合中期財務報表附註 For the six months ended 30 June 2023截至二零二三年六月三十日止六個月 1.公司資料 1.CORPORATE INFORMATION 深圳市海王英特龍生物技術股份有限公司（「本公司」）為一家在中華人民共和國（「中國」）註冊成立的股份有限公司。其註冊辦事處地址為中國深圳市南山區粵海街道麻嶺社區科技中三路1號海王銀河科技大廈1702及其主要營業地點為中國。本公司股份於香港聯合交易所有限公司GEM上市。 ShenzhenNeptunus Interlong Bio-technique Company Limited(the“Company”) is a limited liability company incorporated and domiciledin the People’s Republic of China (the “PRC”). The address of itsregistered office is Suite 1702, Neptunus Yinhe Technology Mansion, 1Keji Middle 3rd Road, Maling Community, Yuehai Sub-district, NanshanDistrict, Shenzhen, the PRC and its principal place of business is PRC.The Company’s shares are listed on GEM of The Stock Exchange ofHong Kong Limited. Theprincipal activities of the Company and its subsidiaries(the“Group”) include the development, production and sales of medicines,theresearch and development of modern